4D Molecular Therapeutics, Inc. Revenue Breakdown
No Revenue Breakdown for FDMT on this site yet.
- 2025-12-31: Others Not split by product in the filing$85.21M100.00%; Total revenue $85.21M.
- 2024-12-31: Total revenue $37.00K.
- 2023-12-31: Others Not split by product in the filing$20.72M100.00%; Total revenue $20.72M.
- 2022-12-31: Others Not split by product in the filing$3.13M100.00%; Total revenue $3.13M.
Source checked: the stored Revenue Breakdown page for FDMT.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $85.21M 100.00% | $85.21M |
| 2024-12-31 | $37.00K | |
| 2023-12-31 | Not split by product in the filing $20.72M 100.00% | $20.72M |
| 2022-12-31 | Not split by product in the filing $3.13M 100.00% | $3.13M |
| 2021-12-31 | Not split by product in the filing $18.04M 100.00% | $18.04M |
| 2020-12-31 | Not split by product in the filing $13.36M 100.00% | $13.36M |
| 2019-12-31 | Not split by product in the filing $6.96M 100.00% | $6.96M |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2026-06-30 | Not split by product $3.78M 100.00% | $3.78M |
| 2026-03-31 | Not split by product $3.05M 100.00% | $3.05M |
| 2025-12-31 | Not split by product $85.09M 100.00% | $85.09M |
| 2025-09-30 | Not split by product $90.00K 100.00% | $90.00K |
| 2025-06-30 | Not split by product $15.00K 100.00% | $15.00K |
| 2025-03-31 | Not split by product $14.00K 100.00% | $14.00K |
| 2024-12-31 | Not split by product $1.00K 100.00% | $1.00K |
| 2024-09-30 | Not split by product $3.00K 100.00% | $3.00K |
| 2024-06-30 | Not split by product $5.00K 100.00% | $5.00K |
| 2024-03-31 | Not split by product $28.00K 100.00% | $28.00K |
| 2023-12-31 | Not split by product -$19.00K 100.00% | -$19.00K |
| 2023-09-30 | Not split by product $20.20M 100.00% | $20.20M |
| 2023-06-30 | Not split by product $239.00K 100.00% | $239.00K |
| 2023-03-31 | Not split by product $298.00K 100.00% | $298.00K |
| 2022-12-31 | Not split by product $1.25M 100.00% | $1.25M |
| 2022-09-30 | Not split by product $500.00K 100.00% | $500.00K |
| 2022-06-30 | Not split by product $162.00K 100.00% | $162.00K |
| 2022-03-31 | Not split by product $1.22M 100.00% | $1.22M |
| 2021-12-31 | Not split by product $92.00K 100.00% | $92.00K |
| 2021-09-30 | Not split by product $1.37M 100.00% | $1.37M |
| 2021-06-30 | Not split by product $14.58M 100.00% | $14.58M |
| 2021-03-31 | Not split by product $2.00M 100.00% | $2.00M |
| 2020-12-31 | Not split by product -$977.00K 100.00% | -$977.00K |
| 2020-09-30 | Not split by product $7.42M 100.00% | $7.42M |
| 2020-06-30 | Not split by product $3.51M 100.00% | $3.51M |
| 2020-03-31 | Not split by product $3.41M 100.00% | $3.41M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |